Posted by Michael Wonder on 06 May 2020
Will Gilead price its coronavirus drug for public good or company profit?
7 May 2020 - Gilead faces a new dilemma in deciding how much it should profit from the only treatment so far proven to help patients infected with the novel coronavirus.
The drug maker earned notoriety less than a decade ago, when it introduced a treatment that essentially cured hepatitis C at a price of $1,000 per pill.
Public outrage over the cost of Sovaldi in 2013 - despite that it was a vast improvement over existing equally expensive therapies - ignited a national debate on fair pricing for prescription medicines that the pharmaceutical industry has fought to deflect ever since.
